Overview

Nemera designs, develops, and manufactures drug delivery devices for pharmaceutical and biotech companies, spanning ophthalmic, nasal, buccal, parenteral, dermal, and inhalation routes. The devices are used to administer medicines and are developed and manufactured in collaboration with customers, often through co-development and customized production in a B2B model. It stands out by offering an end-to-end range of delivery solutions across multiple administration routes, supported by global manufacturing facilities and a wide distribution network. Its goal is to enable safer, more convenient self-administered therapies by providing scalable devices and related design and manufacturing services to partners.

Simplify's Take

What believers are saying

• Rising demand for diabetes and obesity injection pens drives La Verpillière expansion, starting production 2027.
• New Szczecin hall strengthens leadership in GLP-1 drug market for obesity therapies.
• Milfra acquisition in June 2021 expands footprint in Brazil's gynecology and urology markets.

What critics are saying

• SteadyMed's Releev One captures Symbioze market share in GLP-1 delivery within 12-18 months.
• Ypsomed's dose accuracy wins Novo Nordisk contracts, undercutting La Verpillière capacity in 6-12 months.
• SHL Medical's DAI platform displaces Nemera's devices in Eli Lilly obesity pens within 12-24 months.

What makes Nemera unique

• Nemera specializes in drug delivery devices across ophthalmic, nasal, buccal, parenteral, dermal, and inhalation routes.
• Launched Symbioze wearable injector in October 2021 for self-administration needs.
• Introduced UniSpray unidose nasal system for emergency systemic drug delivery.

Help us improve and share your feedback! Did you find this helpful?

YesNo